Slowly Progressing Thrombotic Microangiopathy during Two Years of Treatment with Sunitinib.
- Author:
Min Young KIM
1
;
Heejung CHOI
;
Yoonjung KIM
;
Na Ree KANG
;
Hye Ryoun JANG
;
Ghee Young KWON
;
Wooseong HUH
;
Young Suk PARK
;
Yoon Goo KIM
;
Dae Joong KIM
;
Ha Young OH
;
Jung Eun LEE
Author Information
1. Division of Nephrology, Department of Internal Medicine, Seoul Medical Center, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
VEGF;
Sunitinib;
Thrombotic microangiopathy
- MeSH:
Aged;
Creatinine;
Gastrointestinal Stromal Tumors;
Humans;
Indoles;
Proteinuria;
Pyrroles;
Thrombotic Microangiopathies;
Vascular Endothelial Growth Factor A
- From:Korean Journal of Nephrology
2011;30(5):533-536
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 75-year-old man with mild renal impairment was started on sunitinib for a metastatic gastrointestinal stromal tumor. After 7 months of this therapy, proteinuria became aggravated. Serum creatinine concentration was increased from 1.34 to 2.57 mg/dL 24 months after sunitinib administration. Hematologic features of thrombotic microangiopathy (TMA) were absent. Renal histology revealed endothelial swelling and plasmatic insudation of the glomeruli. Proteinuria and renal function improved after discontinuation of sunitinib. Our experience suggests that TMA associated with sunitinib can be diverse in onset and severity, and that the hematologic features of TMA may be absent.
